Anti-IL-5 Treatment Reduces Infection-Related Adverse Events: A Meta-Analysis of Phase 3 Clinical Trials
- 7 July 2025
- journal article
- review article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (7) , 1632-1633
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Anti-IL-5 Treatment Reduces Infection-Related Adverse Events: A Meta-Analysis of Phase 3 Clinical TrialsThe Journal of Allergy and Clinical Immunology: In Practice, 2025
- Eosinophils promote CD8+ T cell memory generation to potentiate anti-bacterial immunitySignal Transduction and Targeted Therapy, 2024
- Effects of treatment with corticosteroids on human rhinovirus-induced asthma exacerbations in pediatric inpatients: a prospective observational studyBMC Pulmonary Medicine, 2023
- Eosinophils Recruited during Pulmonary Vaccination Regulate Mucosal Antibody ProductionAmerican Journal of Respiratory Cell and Molecular Biology, 2023
- Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory StudiesThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Eosinophils in Health and Disease: A State-of-the-Art ReviewMayo Clinic Proceedings, 2021
- Interleukin-5 in the Pathophysiology of Severe AsthmaFrontiers in Physiology, 2019
- Eosinophils and Respiratory VirusesViral Immunology, 2019
- Anti–IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind StudyAmerican Journal of Respiratory and Critical Care Medicine, 2019